Join
Live feed
·
PRReleasevia Quantisnow
argenx SE logo

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

ByQuantisnow·Wall Street's wire, on your screen.
ARGX· argenx SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARGX (argenx SE) and more on Quantisnow.